Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss

被引:4
作者
Xue, Yan [1 ]
Zhang, Meng [1 ,2 ]
Li, Tao [1 ]
Liu, Feng [3 ,4 ]
Zhang, Li-Xin [1 ]
Fan, Xiao-Ping [1 ,5 ]
Yang, Bao-Hua [1 ]
Wang, Lei [1 ]
机构
[1] Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Infect Dis & Hepatol, 247 Beiyuan Rd, Jinan 250033, Shandong, Peoples R China
[2] Shandong Univ, Jinan Infect Dis Hosp, Cheeloo Coll Med, Dept Hepatol, Jinan 250000, Shandong, Peoples R China
[3] Tianjin Second Peoples Hosp, Dept Liepatol, Tianjin 300000, Peoples R China
[4] Tianjin Inst Hepatol, Tianjin 300000, Peoples R China
[5] Qingdao Sixth Peoples Hosp, Dept Hepatol, Qingdao 266100, Shandong, Peoples R China
关键词
Chronic hepatitis B; Hepatitis B e antigen; Nucleos(t)ide analogs; Cessation; CONSOLIDATION THERAPY; LAMIVUDINE TREATMENT; RELAPSE; DURABILITY; GUIDELINES;
D O I
10.3748/wjg.v27.i14.1497
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND Nucleos(t)ide analogs (NAs) cessation in chronic hepatitis B (CHB) patients remains a matter of debate in clinical practice. Current guidelines recommend that patients with hepatitis B e antigen (HBeAg) seroconversion discontinue NAs after relatively long-term consolidation therapy. However, many patients fail to achieve HBeAg seroconversion after the long-term loss of HBeAg, even if hepatitis B surface antigen (HBsAg) loss occurs. It remains unclear whether NAs can be discontinued in this subset of patients. AIM To investigate the outcomes and factors associated with HBeAg-positive CHB patients with HBeAg loss (without hepatitis B e antibody) after cessation of NAs. METHODS We studied patients who discontinued NAs after achieving HBeAg loss. The Cox proportional hazards model was used to identify predictors for virological relapse after cessation of NAs. The cut-off value of the consolidation period was confirmed using receiver operating characteristic curves; we confirmed the cut-off value of HBsAg according to a previous study. The log-rank test was used to compare cumulative relapse rates among groups. We also studied patients with CHB who achieved HBeAg seroconversion and compared their cumulative relapse rates. Propensity score matching analysis (PSM) was used to balance baseline characteristics between the groups. RESULTS We included 83 patients with HBeAg loss. The mean age of these patients was 32.1 +/- 9.5 years, and the majority was male (67.5%). Thirty-eight patients relapsed, and the cumulative relapse rate at months 3, 6, 12, 24, 36, 60, 120, and 180 were 22.9%, 36.1%, 41.0%, 43.5%, 45.0%, 45.0%, 45.0%, and 52.8%, respectively. Twenty-six (68.4%) patients relapsed in the first 3 mo after NAs cessation, and 35 patients (92.1%) relapsed in the first year after NAs cessation. Consolidation period (>= 24 mo vs < 24 mo) (HR 0.506, P = 0.043) and HBsAg at cessation (>= 100 IU/mL vs < 100 IU/mL) (HR 14.869, P = 0.008) were significant predictors in multivariate Cox regression. In the PSM cohort, which included 144 patients, there were lower cumulative relapse rates in patients with HBeAg seroconversion (P = 0.036). CONCLUSION HBeAg-positive CHB patients with HBeAg loss may be able to discontinue NAs therapy after long-term consolidation, especially in patients with HBsAg at cessation < 100 IU/mL. Careful monitoring, especially in the early stages after cessation, may ensure a favorable outcome.
引用
收藏
页数:11
相关论文
共 23 条
[1]   Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen [J].
Alawad, Ahmad Samer ;
Auh, Sungyoung ;
Suarez, Daniel ;
Ghany, Marc G. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (03) :700-+
[2]   Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection [J].
Chen, Chien-Hung ;
Hung, Chao-Hung ;
Hu, Tsung-Hui ;
Wang, Jing-Houng ;
Lu, Sheng-Nan ;
Su, Pei-Fang ;
Lee, Chuan-Mo .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (11) :1984-+
[3]   Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B [J].
Chi, H. ;
Hansen, B. E. ;
Yim, C. ;
Arends, P. ;
Abu-Amara, M. ;
van der Eijk, A. A. ;
Feld, J. J. ;
de Knegt, R. J. ;
Wong, D. K. H. ;
Janssen, H. L. A. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (09) :867-876
[4]   Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conferences [J].
Cornberg, Markus ;
Lok, Anna Suk-Fong ;
Terrault, Norah A. ;
Zoulim, Fabien ;
Berg, Thomas ;
Brunetto, Maurizia R. ;
Buchholz, Stephanie ;
Buti, Maria ;
Chan, Henry L. Y. ;
Chang, Kyong-Mi ;
Dandri, Maura ;
Dusheiko, Geoffrey ;
Feld, Jordan J. ;
Ferrari, Carlo ;
Ghany, Marc ;
Janssen, Harry L. A. ;
Kennedy, Patrick ;
Lampertico, Pietro ;
Liang, Jake ;
Locarnini, Stephen ;
Maini, Mala K. ;
Mishra, Poonam ;
Papatheodoridis, George ;
Petersen, Joerg ;
Schlottmann, Silke ;
Wang, Su ;
Wedemeyer, Heiner .
JOURNAL OF HEPATOLOGY, 2020, 72 (03) :539-557
[5]   Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study [J].
Dai, Chia-Yen ;
Tseng, Tai-Chung ;
Wong, Grace Lai Hung ;
Huang, Jee-Fu ;
Wong, Vincent Wai Sun ;
Liu, Chun-Jen ;
Yu, Ming-Lung ;
Chuang, Wan-Long ;
Kao, Jia-Horng ;
Chan, Henry Lik Yuen ;
Chen, Ding-Shinn .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (10) :2332-2338
[6]   Efficacy and safety of anti-hepatic fibrosis drugs [J].
Damiris, Konstantinos ;
Tafesh, Zaid H. ;
Pyrsopoulos, Nikolaos .
WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (41) :6304-6321
[7]   EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection [J].
Lampertico P. ;
Agarwal K. ;
Berg T. ;
Buti M. ;
Janssen H.L.A. ;
Papatheodoridis G. ;
Zoulim F. ;
Tacke F. .
JOURNAL OF HEPATOLOGY, 2017, 67 (02) :370-398
[8]  
Jun Baek Gyu, 2016, Korean J Gastroenterol, V67, P28, DOI 10.4166/kjg.2016.67.1.28
[9]   Mathematical investigation of HBeAg seroclearance [J].
Kadelka, Sarah ;
Ciupe, Stanca M. .
MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2019, 16 (06) :7616-7658
[10]   Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion [J].
Kuo, Yuan-Hung ;
Chen, Chien-Hung ;
Wang, Jing-Houng ;
Hung, Chou-Hung ;
Tseng, Po-Lin ;
Lu, Sheng-Nan ;
Changchien, Chi-Sin ;
Lee, Chuan-Mo .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2010, 45 (01) :75-81